semaglutide and antipsychotics Antipsychotic Induced Weight Gain Metabolic Dysfunction Management of obesity with semaglutide

Nevertheless, disparities remain in certain high-risk groups, particularly women and individuals with lower BMI, who appeared less likely to receive SGLT2is despite clear cardiorenal indications

Physiol Rev 1999

J.WalikonisR

As we age, stomach acid production can decline (atrophic gastritis), which makes it harder to extract B12 from food or pills

Clinical trials of brand-name semaglutide showed an average of 15% weight loss plus reduced cardiovascular risk in patients with metabolic syndrome these studies inform how the active ingredient is understood, but the safety, efficacy, and quality data from those trials do not directly apply to compounded preparations